Wednesday, August 20, 2014

FDA Oks expanded use of Regeneron's eye drug

Tue Jul 29, 2014 7:19pm EDT

0 Comments Tweet Share this EmailPrint Related Topics Health »

(Reuters) - Regeneron Pharmaceuticals Inc said the U.S. Food and Drug Administration has approved the expanded use of its eye drug Eylea for the treatment of diabetic macular edema.

The condition causes swelling of an oval spot within the retina in the eyes of patients with diabetes, and can lead to severe vision loss or blindness.

Eylea is already approved in the United States to treat wet age-related macular edema

View the Original article

No comments:

Post a Comment